Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prostate cancer: Charting a course in metastatic castration-sensitive prostate cancer.

× No keyword cloud information.

6 in total

Review 1. Interaction of IGF signaling and the androgen receptor in prostate cancer progression.

Authors: Jennifer D Wu; Kathy Haugk; Libby Woodke; Peter Nelson; Ilsa Coleman; Stephen R Plymate
Journal: J Cell Biochem Date: 2006-10-01 Impact factor: 4.429

2. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.

Authors: Evan Y Yu; Hongli Li; Celestia S Higano; Neeraj Agarwal; Sumanta K Pal; Ajjai Alva; Elisabeth I Heath; Elaine T Lam; Shilpa Gupta; Michael B Lilly; Yoshio Inoue; Kim N Chi; Nicholas J Vogelzang; David I Quinn; Heather H Cheng; Stephen R Plymate; Maha Hussain; Catherine M Tangen; Ian M Thompson
Journal: J Clin Oncol Date: 2015-04-06 Impact factor: 44.544

3. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.

Authors: Mads H Poulsen; Henrik Petersen; Poul F Høilund-Carlsen; Jørn S Jakobsen; Oke Gerke; Jens Karstoft; Signe I Steffansen; Steen Walter
Journal: BJU Int Date: 2014-05-22 Impact factor: 5.588

4. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

Authors: Maha Hussain; Catherine M Tangen; Celestia Higano; Paul F Schelhammer; James Faulkner; E David Crawford; George Wilding; Atif Akdas; Eric J Small; Bryan Donnelly; Gary MacVicar; Derek Raghavan
Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544

5. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.

Authors: Einat Even-Sapir; Ur Metser; Eyal Mishani; Gennady Lievshitz; Hedva Lerman; Ilan Leibovitch
Journal: J Nucl Med Date: 2006-02 Impact factor: 10.057

6. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.

Authors: Ali Afshar-Oromieh; Christian M Zechmann; Anna Malcher; Matthias Eder; Michael Eisenhut; Heinz G Linhart; Tim Holland-Letz; Boris A Hadaschik; Frederik L Giesel; Jürgen Debus; Uwe Haberkorn
Journal: Eur J Nucl Med Mol Imaging Date: 2013-09-27 Impact factor: 9.236

6 in total